Sander Van Deventer

Chief Scientific Officer • Porton Advanced

CSO of Porton Advanced, one of the founding partners and currently an Operating Partner at Forbion Capital Partners; Executive VP Research and Product Development of uniQure, a Nasdaq-listed gene therapy company; Professor of Translational Gastroenterology Leiden University Medical Center. In addition to co-founding Forbion, Sander is a professor in Translational Gastroenterology at the University of Leiden and an accomplished scientist: He authored over 400 peer-reviewed scientific papers, organized several large international scientific conferences, and supervised more than 40 PhD students.In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT N.V.) currently uniQure N.V., developing AAV-based gene therapy products and now listed on Nasdaq (QURE), acting subsequently as CSO, CMO and CEO. He has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera).

Also Speaking

Thomas Bollenbach

Chief Technology Officer • ARMI

Emma Bjorgum

Vice President, Client Services, DNA • Aldevron

Diego Correa

Director, Medical Strategy Lead, Cell & Gene Therapy Center of Excellence • IQVIA

Event Info


Fun Run